PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 17, 20260 citations

Migraine, comorbidity, and risks of severe maternal and neonatal morbidity or mortality: A population-based cohort study.

View Full Paper
CACarmela Melina AlbaneseSBSusan J. BondyCLChristine Lay

Key Points

  • This research aims to assess how migraine and comorbidity affect severe maternal and neonatal morbidity and mortality.
  • Analyzed a cohort of pregnancies in Ontario from 2007 to 2022 (n=2,643,335)
  • Compared outcomes among groups with migraine and other conditions, migraine alone, other conditions alone, and none
  • Utilized modified Poisson regression to estimate risks and interactions between migraine and comorbid conditions
  • 6.8% of women had migraine with comorbid conditions, 3.2% had migraine alone, and 45.7% had only other chronic conditions
  • The incidence of severe maternal morbidity/mortality (SMM-M) was 1.6%, and severe neonatal morbidity/mortality (SNM-M) affected 7.1% of newborns
  • Those with both migraine and comorbidities faced the highest risks for SMM-M (aRRS 1.60) and SNM-M (aRRS 1.43)

Abstract

Migraine is a neurological disease associated with adverse perinatal outcomes. We examined the separate and combined impacts of migraine and comorbidity on risks of severe maternal morbidity/mortality (SMM-M) and severe neonatal morbidity/mortality (SNM-M). This population-based cohort study of pregnancies (n=2,643,335) in Ontario, Canada, 2007-2022, compared females with (1) pre-pregnancy migraine and ≥1 other chronic conditions, (2) migraine alone, (3) other chronic conditions alone, and (4) neither migraine/other chronic conditions (referent) using modified Poisson regression. Attributable proportion due to interaction (aAP) reflected additive interaction between migraine and comorbidity. In the cohort, 6.8% had migraine and other chronic conditions, 3.2% migraine alone, 45.7% other chronic conditions alone, and 44.3% neither. The incidence of SMM-M was 1.6%, while SNM-M affected 7.1% of neonates. Risks of SMM-M and SNM-M were greatest in those doubly exposed (aRRSMM-M 1.60, 95% CI 1.54-1.66; aRRSNM-M 1.43, 1.39-1.46), followed by other chronic conditions alone (aRRSMM-M 1.34, 1.32-1.37; aRRSNM-M 1.30, 1.28-1.32), and migraine alone (aRRSMM-M 1.13, 1.07-1.20; aRRSNM-M 1.07, 1.04-1.11). Additive interaction was small for SMM-M (aAP 7.4%, 2.2-12.5) and SNM-M (aAP 3.7%, 0.3-6.9). Although synergistic effects were small, findings suggest individuals with migraine and comorbidity could benefit from preconception and perinatal supports to reduce their risks of perinatal complications.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Albanese et al. (2026) studied this question.

synapsesocial.com/papers/696b26d7d2a12237a934a11bhttps://doi.org/10.1093/aje/kwag008
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Differential impact of migraine on severe maternal morbidity and postpartum readmissions: Insights from a national cohort study2026
  2. 2Multiple Maternal Chronic Conditions and Risk of Severe Neonatal Morbidity and Mortality2026
  3. 3Migraine and risk of adverse obstetric outcomes: a matched cohort study of English linked electronic health records2026
  4. 4Multiple Chronic Conditions Before Pregnancy and Risk of Adverse Maternal Health Outcomes: Population‐Based Cohort Study2025
  5. 5Identification of common genetic and molecular signatures in migraine and comorbid conditions2026 · 2 citations